World's first microbiome study has revealed the links between lifestyle and gut flora.
Through the analysis of more than 1,000 human stool samples, a team of researchers led by professor Jeroen Raes (VIB/VUB/KU Leuven) has identified 69 factors that are linked to gut flora composition. These results provide important information for future disease research and clinical studies.
Raes said, "The research has given a tremendous amount of new insight into the microbiota composition of normal people. Analyzing the 'average' gut flora is essential for developing gut bacteria-based diagnostics and drugs. You need to understand what's normal before you can understand and treat disease."
Stool transit time showed the strongest association to gut flora composition. Also diet was an important factor, with most associations related to fiber consumption. One of the many surprising findings was the association of a particular bacterial group with a preference for dark chocolate!
"The Belgian chocolate effect," Raes laughs. "As many readers might expect, we also found an association between gut flora composition and beer consumption."
Other project results incite deeper investigation, such as the relationship between the gut flora and factors linked to oxygen uptake capacity. Medication also had a strong link to the gut flora profile.
The Raes Lab researchers not only identified associations with antibiotics and laxatives, but also with hay fever drugs and hormones used for anticonception or alleviation of menopause symptoms. Remarkably, early life events such as birth mode or whether or not volunteers were breast-fed as babies were not reflected in adult microbiota composition.
Raes noted, "These results are essential for disease studies. Parkinson's disease, for example, is typically associated with a longer intestinal transit time, which in turn impacts microbiota composition. So to study the microbiota in Parkinson's disease, you need to take that into account. These and many other observations can help scientists in their research into future therapies."
The study is published in the upcoming issue of the leading academic journal Science.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
